Center for Human Reproduction
14
0
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
35.7%
5 terminated/withdrawn out of 14 trials
44.4%
-42.1% vs industry average
29%
4 trials in Phase 3/4
75%
3 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Ovarian Function Following Intraovarian Injection of PRP
Role: lead
Study of PRP in Women With Evidence of Diminished Ovarian Reserve
Role: lead
Injections of Autologous PRP in Women With Primary Ovarian Insufficiency
Role: lead
Effect of Influenza Vaccination on IVF Outcomes - IVF
Role: lead
Effect of Testosterone Treatment on Embryo Quality
Role: lead
Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF
Role: lead
Effect of Influenza Vaccination on Donor Egg Recipient Outcomes
Role: lead
Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF
Role: lead
Comparison Of The Embryoscope Time-Lapse System With Standard Embryo Culture
Role: lead
Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility
Role: lead
Randomized Controlled Trial Comparing Embryonic Quality in rFSH Versus hMG in IVF Protocol With GnRH Antagonist
Role: collaborator
Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles?
Role: lead
Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)
Role: lead
A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)
Role: lead
All 14 trials loaded